Giant sinkholes in a South Dakota neighborhood make families fear for their safety
For a week, New York will be center of money-focused fight to slow climate change
Hungarian intelligence agency interviewed CEO linked to exploding Hezbollah pagers
Hundreds of parachutists drop over Dutch heath to commemorate World War II operation
An Israeli strike on a school kills at least 22 people, Gaza Health Ministry says
US election uncertainty clouds UN climate finance progress
Lando Norris beats Max Verstappen for pole position at F1's Singapore Grand Prix
Jackson marks 50th appearance for Chelsea with 2 goals in 3-0 win at West Ham
Oktoberfest is open. The world’s largest folk festival begins after ceremonial keg-tapping
(CNN) — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
Donanemab, made by Indianapolis-based Eli Lilly, works by helping the body remove amyloid plaque buildup in the brain, a hallmark of Alzheimer’s disease.
Lilly said it will be sold under the name Kisunla and would cost $695 per vial before insurance, what would amount to $12,522 for a six-month course or about $32,000 for a year.
This is a developing story and will be updated.
The-CNN-Wire
™ & © 2024 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
